Psychedelic medicine and neuroplastic agents

The pharmacological starting point is not in dispute. Classical psychedelics — psilocin, LSD, DMT, mescaline — are agonists at the serotonin 5-HT2A receptor, a Gq-coupled receptor densely expressed on layer V pyramidal neurons of the cortex. Selective 5-HT2A antagonists such as ketanserin block the subjective effects in humans, which fixes the receptor as necessary for the experience. What is genuinely at issue is whether the receptor’s downstream cellular effect, rather than the experience, is what produces the clinical response.

The plasticity claim

In cultured cortical neurons and in rodent cortex, single doses of these compounds increase dendritic spine density and dendritic arbour complexity, with effects appearing within a day and persisting for weeks. The signalling implicated runs through 5-HT2A to TrkB and downstream mTOR, the same node engaged by ketamine’s rapid antidepressant action, and blocking mTOR abolishes the structural change. This is the basis for the term psychoplastogen: a small molecule producing rapid, sustained cortical structural plasticity, proposed as the substrate for durable improvement in disorders where cortical atrophy is a documented feature of chronic depression and stress.

An elegant piece of the puzzle concerns location. Serotonin itself is a potent 5-HT2A agonist yet is not psychoplastogenic. Work published in 2023 argued that the relevant receptor pool is intracellular, and that psychedelics engage it because they are lipophilic and membrane-permeant while serotonin, being charged at physiological pH, is not; adding a transporter that carries serotonin into the cell conferred plasticity effects on it. If this holds, it explains why hallucinogenic potential and plasticity might be separable pharmacological properties, and it is the explicit rationale for non-hallucinogenic analogues now in development.

Why the evidence is hard to secure

The constraint here is methodological, not chemical, and it is more severe than in most of medicine. A compound producing several hours of unmistakable altered consciousness cannot be blinded: participants and often raters know their assignment, and expectancy in trials of subjective psychiatric endpoints is a large, well-documented effect. Active comparators such as low-dose niacin or very low doses of the drug itself reduce but do not remove the problem.

Two further confounds are structural. These are administered inside a psychological support protocol, so the trial tests a drug-plus-therapy package and cannot cleanly attribute effect to either component. And the therapeutic context creates the conditions in which any adverse event involving suggestibility must be scrutinised — a concern that contributed directly to a US regulatory rejection in 2024 of an MDMA-assisted therapy application, on trial-conduct and evidence-integrity grounds rather than on a failed efficacy read-out.

Safety has its own mechanism-level limit. Chronic 5-HT2B agonism is a known cause of valvular heart disease, established from fenfluramine and ergot-derived dopamine agonists, so any compound intended for repeated dosing requires demonstrated 5-HT2B selectivity. The honest summary is that the receptor pharmacology is solid, the cellular plasticity finding is reproducible, and the causal link from either to durable clinical benefit remains the open question.

See also the technology article at /technology/psychedelic-medicine-neuropsychiatric-biologics/.